Hypertensive disease
Roche and Alnylam Push Zilebesiran into Phase III Trial Despite Mixed Phase II Hypertension Data
Roche; Alnylam; zilebesiran; hypertension; RNAi therapeutics; KARDIA-3; Phase II trial; Phase III trial; cardiovascular outcomes; ZENITH trial
AstraZeneca gears up for FDA filing after baxdrostat’s phase 3 hypertension success
AstraZeneca; baxdrostat; hypertension; FDA filing; aldosterone synthase inhibitor; phase 3 trial; regulatory approval
AstraZeneca’s Baxdrostat Achieves Pivotal Phase 3 Success for Hypertension, Validating $1.3B CinCor Acquisition
AstraZeneca; baxdrostat; CinCor Pharma; hypertension; high blood pressure; phase 3 trial; aldosterone synthase inhibitor; $1.3 billion acquisition; clinical trial win; uncontrolled hypertension; treatment-resistant hypertension
Chronic care startup Omada Health files to go public
Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health
Mineralys Phase 3 blood pressure pill data support potential FDA approval
United States Food and Drug Administration, Launch-HTN, Uncontrolled, Hypertensive disease, Approved
Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug
Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration
NFL Legend Jerome Bettis Joins CDC Foundation’s “Live to the Beat” Campaign to Tackle Heart Health in Black Community
Jerome Bettis, CDC Foundation, Live to the Beat, cardiovascular disease, Black community, hypertension, heart health, NFL
Idorsia’s Restructuring Efforts Continue: Layoffs On Track Despite Delayed Sale of Hypertension Drug Tryvio
Idorsia, Restructuring, Layoffs, Tryvio, Hypertension drug, Aprocitentan, Cost-saving measures, Financial sustainability
Novo Nordisk Terminates Development of Kidney Disease Drug Ocedurenone After Phase 3 Failure
Novo Nordisk, ocedurenone, kidney disease, hypertension, Phase 3 trial, CLARION-CKD, drug development failure
CMS Approves Transitional Pass-Through Payments for Renal Denervation Systems from Medtronic and Recor Medical
Renal Denervation Systems, CMS, Transitional Pass-Through Payments, Medtronic, Recor Medical, Hypertension Treatment